Burney Co. grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 9.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 683 shares of the pharmaceutical company’s stock after purchasing an additional 58 shares during the quarter. Burney Co.’s holdings in Vertex Pharmaceuticals were worth $238,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in VRTX. ST Germain D J Co. Inc. bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth $26,000. OFI Invest Asset Management bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth $25,000. Marquette Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth $27,000. Cornerstone Planning Group LLC bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth $33,000. Finally, NBC Securities Inc. bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth $34,000. 90.77% of the stock is owned by hedge funds and other institutional investors.
Vertex Pharmaceuticals Stock Performance
Shares of NASDAQ VRTX opened at $422.91 on Friday. The stock has a market cap of $108.98 billion, a price-to-earnings ratio of 30.45, a P/E/G ratio of 2.31 and a beta of 0.36. The company has a current ratio of 3.99, a quick ratio of 3.89 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a 1-year low of $283.60 and a 1-year high of $448.40. The stock’s 50-day moving average is $411.25 and its 200 day moving average is $374.82.
Wall Street Analysts Forecast Growth
Several brokerages have commented on VRTX. JPMorgan Chase & Co. raised their target price on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. HC Wainwright raised their target price on Vertex Pharmaceuticals from $397.00 to $457.00 and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Barclays raised their target price on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Evercore ISI downgraded Vertex Pharmaceuticals from an “outperform” rating to an “in-line” rating and raised their target price for the stock from $436.00 to $438.00 in a research note on Tuesday, February 6th. Finally, BMO Capital Markets raised their target price on Vertex Pharmaceuticals from $389.00 to $415.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 7th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $412.62.
Insider Activity at Vertex Pharmaceuticals
In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 6,648 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $419.07, for a total value of $2,785,977.36. Following the transaction, the chairman now directly owns 2,423 shares of the company’s stock, valued at approximately $1,015,406.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.40% of the stock is currently owned by insiders.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations.
- Five stocks we like better than Vertex Pharmaceuticals
- Russell 2000 Index, How Investors Use it For Profitable Trading
- MarketBeat Week in Review – 2/5 – 2/9
- How to Buy Gold Stock and Invest in Gold
- Cloudflare results spark analysts reset: 25% upside ahead
- Learn Technical Analysis Skills to Master the Stock Market
- Beyond Nvidia: The hidden stars with 200% earnings growth
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.